<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_lopinavir_ritonavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:43 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Lopinavir/Ritonavir</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, M.D.</author>
<br>
<span class="display_date">03-25-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>
<B>Available formulations in Zambia: </B>133.3 mg + 33.3 mg capsule; 400 mg + 100 mg/5 ml oral liquid. <B></B>
</li>
<li>LPV/r plus <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> or <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> or <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> is recommended second line regimen after <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>/<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> failure. </li>
<li>Refer to an HIV specialist if pt unable to tolerate LPV/r-based second line regimen. </li>
<li>PI-based regimen recommended for treatment of HIV-2 infection. </li>
<li>Store capsules and solution in the refrigerator at 2-8<SUP>&ordm; </SUP>C (36-46<SUP>&ordm;</SUP><SUP>&nbsp;</SUP>F) until expiration date or at room temperature for up to 2 months. </li>
<li>Avoid exposing capsules and solution to excessive heat. </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm.D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV infection in combination with other antiretrovirals.</li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top"><I>Kaletra (U.S); </I>&nbsp;Aluvia (developing countries)</TD><TD valign="top">Lopinavir/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A> (LPV/r) </TD><TD valign="top">Abbott Laboratories</TD><TD>oral</TD><TD>solution</TD><TD>400 mg LPV/100 mg <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> per 5 mL</TD><TD>$12.93 per 5 mL</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral </TD><TD>tablet</TD><TD>200 mg LPV/50 mg <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A></TD><TD>$6.90</TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>
<ul>
<li>400/100 mg&nbsp;2 tabs bid with or without food OR 5&nbsp;ml bid with food. </li>
<li>Consider 800/200 mg (4 tabs or 10 mL liquid) qd with food (PI-naive pts only). </li>
<li>With <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>: Consider LPV/r 600/150 mg (3 tabs) + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs, especially in PI-experienced pts. Standard doses acceptable for PI naive pts. </li>
<li>With <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: Consider LPV/r 600/150 mg (3 tabs) + <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> 200 mg bid, especially in PI-experienced pts. Standard doses acceptable for PI naive pts. . </li>
<li>With <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>: LPV/r 400/100 mg (2&nbsp;tabs) bid + <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> 600 or 666 mg bid. </li>
<li>With <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>: LPV/r 400/100 mg (2&nbsp;tabs) bid + <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 1000 mg bid. </li>
<li>With <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A>: Not recommended by some. Consider LPV/r 600/150 mg (3 tabs) with <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> 1400 mg bid (high rate of GI intolerance).</li>
<li>With <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>: Generally not recommended. Consider LPV/r 600/150 mg (3 tabs) + <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> 1250 mg bid. </li>
<li>With <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>: LPV/r 400/100 mg (2 tabs) bid + <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> 300 mg qd.</li>
<li>With <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV</A>/r: co-administration not recommended.</li>
<li>No data with <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>
</li>
<li>With DRV/r: co-administration not recommended. </li>
<li>With etravirine: usual dose. Unclear clinical significance, but manufacturer recommends co-administration with caution. </li>
<li>With raltegravir: consider usual dose with close monitoring. </li>
<li>With maraviroc: LPV/r 400/100 mg bid + maraviroc 150 mg bid. </li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>Usual dose <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>No data; usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>No data; usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>Usual dose (not removed with HD). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>No data; usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/diarrhea8e47.html?contentInstanceId=432753">Diarrhea</A> in 14-24% of pts using capsules. In a questionnaire survey, 50% reduction in frequency and severity of diarrhea when pts switched from the caps to tabs.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/nausea_vomiting1649.html?contentInstanceId=432759">Nausea, vomiting</A>, abdominal pain, asthenia, and headache</li>
<li>Elevated triglycerides (12-22%) and cholesterol (14-22%)</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/diabetes_mellitus_and_insulin_resistance382a.html?contentInstanceId=432783">Insulin resistance</A>, hyperglycemia, and <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/diabetes_mellitus_and_insulin_resistance382a.html?contentInstanceId=432783">diabetes</A>&nbsp;</li>
<li>Hepatitis (10-12%) </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>Pancreatitis (unclear association) </li>
<li>Rash </li>
<li>Nephrolithiasis (unclear association) </li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>Substrate, inhibitor, and likely an inducer of CYP3A4 and glucoronyl transferase. May also weakly induce CYP2C9 and CYP2C19 and weakly inhibit CYP2D6 (clinical significance unknown). LPV/r generally increases serum levels of drugs that are substrates of CYP3A4 (but reduction in serum levels have also occurred). Drugs that are inducers of CYP3A4 may decrease serum levels of LPV/r. Drugs that are inhibitors of CYP3A4 may increase serum levels of LPV/r. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">Abacavir (ABC)</A>
          </B></TD><TD valign="top">May increase serum levels of alprazolam.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider  alternative benzodiazepine (i.e lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">Delavirdine (DLV)</A>
          </B></TD><TD valign="top">May increase LPV levels.</TD><TD valign="top">No data. Use standard dose; consider TDM.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">Efavirenz (EFV)</A>
          </B></TD><TD valign="top">LPV/r AUC decreased by 19% and Cmin decreased by 39%; <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> levels unaffected.</TD><TD valign="top">Dose: Consider LPV/r 600/150 mg (3 tabs) bid + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs, especially in pts with PI resistance. Standard doses may be acceptable in PI-naive pts. LPV/r 600/150mg bid + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs resulted in 32% higher LPV Cmin compared to LPV/r 400/100 mg bid (historical control).</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">Indinavir (IDV)</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC increased by 20% and Cmin increased by 46%; <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> Cmin increased by 247%. </TD><TD valign="top">Dose: <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> 600 mg or 666 mg bid + LPV/r 400/100 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/metronidazoleb50a.html?contentInstanceId=434168">Metronidazole</A>
          </B></TD><TD valign="top">Disulfiram-like reaction.</TD><TD valign="top">Applies to LPV liquid formulation. Warn pts of LPV alcohol content (liquid). Use LPV/r caps.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>
          </B></TD><TD valign="top">LPV AUC decreased by 27% and Cmin decreased by 33% NFV Cmin increased by 113%.</TD><TD valign="top">Do not co-administer or consider LPV/r 600/150 mg (3 tabs) + <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> 1250 mg bid with TDM</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">Nevirapine (NVP)</A>
          </B></TD><TD valign="top">LPV AUC decreased by 22%. NVP levels unaffected.</TD><TD valign="top">Dose: Consider LPV/r 600/150 mg (3 tabs) bid + <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> standard dose, especially in pts. with PI resistance. Standard doses may be acceptable for PI-naive pts.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">Rifampin</A>
          </B></TD><TD valign="top">LPV/r AUC decreased by 75% and Cmin decreased by 99%.</TD><TD valign="top">Generally not recommended. With co-administration consider LPV/r 400/100 mg (3 caps) +&nbsp;<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 300 mg bid (note: monitor LFTs, GI intolerance, and lipids). A more recent study of LPV/r 3 to 4 tabs BID + rifampin found high incidence of nausea, vomiting, and grade 4 LFTs elevation. Rifabutin &nbsp;preferred w/ LPV/r co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">Saquinavir (SQV)</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> AUC increased by 836% and Cmin increased by 1700%.</TD><TD valign="top">Dose: <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 1000 mg bid + LPV/r 400/100 mg bid. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/fluconazoled462.html?contentInstanceId=434183">Fluconazole</A>
          </B></TD><TD valign="top">Interaction unlikely. </TD><TD valign="top">Use standard doses for both drugs. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">Atazanavir (ATV) </A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> geometric mean Cmin increased by 45% with LPV/r 400/100 mg BID co-administration (compared to <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>-r 300/100 mg QD). LPV PK comparable to historical data. </TD><TD valign="top">Dose: <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> 300 mg QD + LPV/r 400/100 mg BID </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">Fosamprenavir (FPV) </A>
          </B></TD><TD valign="top">Decreased APV and LPV levels </TD><TD valign="top">Not recommended by some. Consider FPV 1400 mg bid + LPV/r 600/150 mg (3 tabs) &nbsp;bid (and consider TDM). </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV (tipranavir) </A>
          </B></TD><TD valign="top">LPV AUC decreased by 49% (studied dose TPV 500 mg bid + LPV/r 400/100 mg bid.) </TD><TD valign="top">Not generally recommended. LPV/r 400/100 mg BID with TPV/r 500/200 mg BID (additional <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg BID) resulted in "adequate" LPV Cmin, but significant interpatient variability and small sample size suggest confirmation of these findings before this dosing regimen can be recommended. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">Darunavir</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">DRV</A> AUC and Cmin decreased 53% and 65%, respectively. LPV AUC and Cmin increased 37% and 72%, respectively.</TD><TD valign="top">Avoid co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Alfuzosin </B></TD><TD valign="top">May significantly increase alfuzosin levels. </TD><TD valign="top">Contraindicated. Consider doxazosin and terazosin for BPH (with close monitoring). </TD>
</TR>
<TR>
<TD valign="top"><B>Amiodarone</B></TD><TD valign="top">May significantly increase amiodarone serum level.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to case report of increased amiodarone levels with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> co-administration. <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>, APV, and <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>&nbsp;manufacturers recommend against use of amiodarone, but all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the same potential of significantly increasing amiodarone serum levels. If co-administration can not be avoided, monitor for amiodarone ADR (PFTs and TSH). Consider monitoring serum levels of amiodarone, but its long half-life may make titration difficult.</TD>
</TR>
<TR>
<TD valign="top"><B>Amlodipine</B></TD><TD valign="top">May increase serum levels of amlodipine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and DLV have the potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Amprenavir (APV)
          </B></TD><TD valign="top">APV Cmin higher than unboosted APV (1200 mg bid; 0.8 mcg/mL vs. 0.32 mcg/mL) but lower than boosted APV (APV 600 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>100 mg bid); LPV AUC decreased by 30-50%.</TD><TD valign="top">Co-administration generally not recommended. Dose: LPV/r 600/150 mg (3 tabs) OR + APV 750 mg bid (consider TDM). See also fosamprenavir.</TD>
</TR>
<TR>
<TD valign="top"><B>Artemether (artemisinin)</B></TD><TD valign="top">May increase serum levels of artemether.</TD><TD valign="top">Data available only for <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>. Co-administration of <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> with artesunate + <A class="headLines" target="_new" href="../antimicrobial_agents/amodiaquine305e.html?contentInstanceId=434591">amodiaquine</A> resulted in significant LFT elevations. Close monitoring for artemether toxicity (bone marrow suppression, bradycardia and seizure).&nbsp;</TD>
</TR>
<TR>
<TD valign="top"><B>Astemizole</B></TD><TD valign="top">May significantly increase astemizole serum levels.</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratadine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Atorvastatin
          </B></TD><TD valign="top">Atorvastatin AUC increased by 488%.</TD><TD valign="top">Use with caution at lower end of dosing range (10-40 mg/d). Monitor for&nbsp;Sx of atorvastatin toxicity (rhabdomyolysis and myopathy). Consider alternative agents: pravastatin, fluvastatin, or rosuvastatin.</TD>
</TR>
<TR>
<TD valign="top"><B>Azathioprine</B></TD><TD valign="top">Interaction unlikely.</TD><TD valign="top">Applies to all PIs and NNRTIs: Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Bepridil</B></TD><TD valign="top">May significantly increase bepridil serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. The manufacturer of <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>, <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>, and APV does not recommend bepridil co-administration, this contraindication should extend to all PIs and DLV since a significant increase in bepridil serum level can result in pro-arrhythmic events such as VT, PVC, and VFib.</TD>
</TR>
<TR>
<TD valign="top"><B>Carbamazepine</B></TD><TD valign="top">LPV serum levels may be significantly decreased.</TD><TD valign="top">Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). With coadministration, monitor anticonvulsants level and consider TDM of LPV.</TD>
</TR>
<TR>
<TD valign="top"><B>Chlordiazepoxide</B></TD><TD valign="top">May increase serum levels of chlordiazepoxide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider an alternative benzodiazepine (lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cisapride</B></TD><TD valign="top">May significantly increase cisapride serum levels.</TD><TD valign="top">Contraindicated due to potential for cardiac arrhythmias. Recommended alternative: metoclopramide.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Clorazepate
          </B></TD><TD valign="top">May increase serum levels of clorazepate.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider an alternative benzodiazepine (lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclophosphamide</B></TD><TD valign="top">May increase serum level of cyclophosphamide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> resulting in a 50% increase in cyclophosphamide serum levels. Since all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of increasing cyclophosphamide levels, close monitoring of cyclophosphamide-induced toxicity is recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclosporine</B></TD><TD valign="top">May significantly increase serum levels of cyclosporine.</TD><TD valign="top">Applies to all PIs: Monitor serum levels of cyclosporine closely with co-administration. Cyclosporine dose may need to be decreased.</TD>
</TR>
<TR>
<TD valign="top"><B>Desipramine</B></TD><TD valign="top">Desipramine AUC may be increased. LPV not affected.</TD><TD valign="top">Clinical significance unknown. Monitor for desipramine adverse drug reaction and serum level (if available). Consider alternative antidepressant: escitalopram, citalopram, sertraline, or fluoxetine.</TD>
</TR>
<TR>
<TD valign="top"><B>Digoxin </B></TD><TD valign="top">Digoxin AUC increased 81% with LPV/r co-administration. </TD><TD valign="top">Monitor digoxin plasma concentration closely with co-administration </TD>
</TR>
<TR>
<TD valign="top"><B>Diltiazem</B></TD><TD valign="top">May increase serum levels of diltiazem.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and DLV have the potential of prolonging PR interval with diltiazem co-administration. Diltiazem should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Disopyramide</B></TD><TD valign="top">May increase disopyramide serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Monitor disopyramide serum levels (target: 2 to 7.5 mcg/mL).</TD>
</TR>
<TR>
<TD valign="top"><B>Docetaxel</B></TD><TD valign="top">May increase serum levels of docetaxel.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Dofetilide</B></TD><TD valign="top">May significantly increase serum levels of dofetilide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution. Monitor QTc closely and adjust dofetilide dosing based on QTc prolongation and renal function. Consider an alternative class III antiarrhythmic such as bretylium or ibutilide.</TD>
</TR>
<TR>
<TD valign="top"><B>Echinacea </B></TD><TD valign="top">May decrease LPV/r serum levels. Echinacea (400 mg 4xd) decreased CYP3A4 substrate (midazolam) by 23%.</TD><TD valign="top">Clinical significance unknown but should avoided until the safety of this combination is further evaluated.</TD>
</TR>
<TR>
<TD valign="top"><B>Ergot Alkaloid</B></TD><TD valign="top">May significantly increase serum levels of ergotamine resulting in acute ergot toxicity.</TD><TD valign="top">Contraindicated. Consider alternative agent for migraine such as sumatriptan (but not eletriptan since it is a CYP3A4 substrate and significant drug-drug interaction occurred with CYP3A4 inhibitor).</TD>
</TR>
<TR>
<TD valign="top"><B>Estazolam</B></TD><TD valign="top">May increase serum levels of estazolam.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">DLV</A>: Consider an alternative benzodiazepine (i.e lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Ethinyl estradiol</B></TD><TD valign="top">Ethinyl estradiol AUC decreased by 42%.</TD><TD valign="top">Recommend an alternative or additional form of contraception.</TD>
</TR>
<TR>
<TD valign="top"><B>Ethosuximide</B></TD><TD valign="top">May increase serum levels of ethosuximide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider switching to valproic acid for the treatment of absence seizure.</TD>
</TR>
<TR>
<TD valign="top"><B>Etoposide</B></TD><TD valign="top">May increase serum levels of etoposide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Etravirine&nbsp;</B></TD><TD valign="top">LPV AUC decreased 20%. Etravirine area under the curve increased 17%. </TD><TD valign="top">Clinical significance unclear, but the manufacturer recommends co-administration with caution. Usual dose recommended. </TD>
</TR>
<TR>
<TD valign="top"><B>Ezetimibe</B></TD><TD valign="top">No significant interaction</TD><TD valign="top">Observational PK substudy involving 6 patients did not find reduction in LPV AUC. </TD>
</TR>
<TR>
<TD valign="top"><B>Ezetimibe </B></TD><TD valign="top">No significant change in lopinavir/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A> trough measurements after the addition of ezetimibe. </TD><TD valign="top">Separate administration time if possible. Observation pharmacokinetic substudy that needs confirmation </TD>
</TR>
<TR>
<TD valign="top"><B>Felodipine</B></TD><TD valign="top">May increase serum levels of felodipine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum level (this led to PR interval prolongation). All PIs and DLV have the potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Fentanyl</B></TD><TD valign="top">May significantly increase fentanyl serum levels.</TD><TD valign="top">Use with caution. Consider morphine.</TD>
</TR>
<TR>
<TD valign="top"><B>Flecainide</B></TD><TD valign="top">May significantly increase serum levels of flecainide.</TD><TD valign="top">Contraindicated.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Flurazepam
          </B></TD><TD valign="top">May increase serum levels of flurazepam.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider an alternative benzodiazepine (i.e lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Fluticasone </B></TD><TD valign="top">With <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> co-administration fluticasone AUC and Cmax increased by 350-fold and 25-fold, respectively. </TD><TD valign="top">Data limited to <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> co-administration. With chronic <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> co-administration plasma cortisol AUC decreased by 86%. Cushing's syndrome and adrenal suppression have been reported. Co-administration not recommended by manufacturer. Avoid long-term co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Food</B></TD><TD valign="top">Increases LPV AUC.</TD><TD valign="top">LPV/r tabs can be taken with or without food.</TD>
</TR>
<TR>
<TD valign="top"><B>Garlic supplement </B></TD><TD valign="top">49% and 51% reduction of <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> Cmin and AUC, respectively when co-administered with garlic supplement (3.5 mg bid). <BR>
</TD><TD valign="top">Studies only done with <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> but garlic may affect the serum levels of other PIs or NNRTIs. Co-administration of garlic supplements should be avoided with PIs and NNRTIs. </TD>
</TR>
<TR>
<TD valign="top"><B>Granisetron</B></TD><TD valign="top">May increase serum levels of granisetron.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Due to the large therapeutic index of granisetron, potential interaction is unlikely to be clinically significant.</TD>
</TR>
<TR>
<TD valign="top"><B>Heroin (Diamorphine)</B></TD><TD valign="top">Drug interactions unlikely.</TD><TD valign="top">Applies to PIs and NNRTIs: Interaction unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Ifosphamide</B></TD><TD valign="top">May increase serum levels of ifosphamide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Irinotecan</B></TD><TD valign="top">May increase irinotecan serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Co-administration of <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> is contraindicated by manufacturer. All PIs and DLV also have the potential for significant interaction with Irinotecan, therefore co-administration should be done with extreme caution.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Itraconazole
          </B></TD><TD valign="top">CYP3A4 inhibitor and substrate - bidirectional inhibition with increase levels of PIs and itraconazole. <BR>
<BR>
</TD><TD valign="top">Use standard dose with itraconazole and LPV/r co-administration. Consider monitoring itraconazole levels.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Ketoconazole
          </B></TD><TD valign="top">LPV increased 13%. Ketoconazole increased by 3-fold.</TD><TD valign="top">Do not exceed ketoconazole 200 mg qd with LPV/r co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Lamotrigine</B></TD><TD valign="top">Lamotrigine Cmin decreased by 56% </TD><TD valign="top">Increase lamotrigine dose to 200 mg bid when coadministering with LPV/r. </TD>
</TR>
<TR>
<TD valign="top"><B>Lidocaine</B></TD><TD valign="top">May increase antiarrhythmic serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution, monitor lidocaine serum levels (target: 1.5 to 6 mcg/mL) with co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Lovastatin
          </B></TD><TD valign="top">May significantly increase lovastatin levels.</TD><TD valign="top">Contraindicated. Recommended alternatives include pravastatin, rosuvastatin, and fluvastatin (and possibly atorvastatin - start at 10 mg qd). Monitor for adverse effect due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Maraviroc </B></TD><TD valign="top">Maraviroc AUC increased 283% </TD><TD valign="top">Dose: MVC 150 mg bid + LPV/r 400/100 mg bid. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Mefloquine
          </B></TD><TD valign="top">May increase serum levels of mefloquine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Monitor mefloquine serum levels. Monitor for mefloquine toxicity (i.e dizziness, LFTs, and periodic ophthalmic examination).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Methadone
          </B></TD><TD valign="top">Methadone AUC decreased by 26-36%.</TD><TD valign="top">No withdrawal Sx observed in 2 of 3 studies. Standard methadone dose recommended, but may need to increase methadone dose in a small subset of pts.</TD>
</TR>
<TR>
<TD valign="top"><B>Mexiletine</B></TD><TD valign="top">May increase antiarrhythmic serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution. Monitor EKG and serum levels. Serum levels exceeding 1.5 to 2 mcg/mL have been associated with an increased risk of toxicity.</TD>
</TR>
<TR>
<TD valign="top"><B>Midazolam</B></TD><TD valign="top">May significantly increase midazolam levels.</TD><TD valign="top">Concurrent administration of midazolam is contraindicated. Consider alternative benzodiazepines&nbsp;(temazepam, oxazepam, or lorazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Milk thistle </B></TD><TD valign="top">Data limited to an interaction study with milk thistle and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>. <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC: unchanged and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> Cmin decreased by 47%. <BR>
</TD><TD valign="top">Unknown effect on LPV serum levels. Avoid co-administration with PIs and NNRTIs until it can be further evaluated. </TD>
</TR>
<TR>
<TD valign="top"><B>Mirtazapine</B></TD><TD valign="top">May increase serum levels of mirtazapine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine.)</TD>
</TR>
<TR>
<TD valign="top"><B>Mycophenolate</B></TD><TD valign="top">Interaction unlikely. No significant interaction observed with NVP.</TD><TD valign="top">Applies to all PIs and NNRTI: No significant interaction observed with <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Nefazodone</B></TD><TD valign="top">May increase serum levels of nefazodone.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine).</TD>
</TR>
<TR>
<TD valign="top"><B>Nifedipine</B></TD><TD valign="top">May increase serum levels of nifedipine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and DLV have the potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Nisoldipine</B></TD><TD valign="top">May increase serum levels of nisoldipine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and DLV have the potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Omeprazole</B></TD><TD valign="top">No change in lopinavir/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A> pharmacokinetics.&nbsp;</TD><TD valign="top">Use standard dose LPV/r tablet with omeprazole co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Paclitaxel</B></TD><TD valign="top">May increase serum levels of paclitaxel. Reports of toxicity associated with LPV/r and paclitaxel co-administration.</TD><TD valign="top">Monitor closely for paclitaxel-induced toxicity.</TD>
</TR>
<TR>
<TD valign="top"><B>PCP</B></TD><TD valign="top">May significantly increase serum levels of PCP.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Avoid all illicit drug use for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenobarbital</B></TD><TD valign="top">LPV levels may be significantly decreased.</TD><TD valign="top">Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). Monitor anticonvulsants level when applicable and consider TDM of LPV.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenytoin</B></TD><TD valign="top">LPV AUC decreased by 33%. Phenytoin AUC decreased by 31%.</TD><TD valign="top">Avoid co-administration. Monitor anticonvulsants levels. Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). Consider empirically increasing LPV/r to 600/150 mg (3 tabs) bid (with TDM). </TD>
</TR>
<TR>
<TD valign="top"><B>Pimozide</B></TD><TD valign="top">May significantly increase pimozide serum levels resulting in QTc prolongation.</TD><TD valign="top">Contraindicated. Consider alternative: Olanzapine.</TD>
</TR>
<TR>
<TD valign="top"><B>Prednisone </B></TD><TD valign="top">May increase prednisone serum concentration. </TD><TD valign="top">May require dose adjustment with long-term co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Propafenone</B></TD><TD valign="top">May significantly increase serum levels of propafenone.</TD><TD valign="top">Contraindicated.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Quinidine
          </B></TD><TD valign="top">May increase antiarrhythmic serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Contraindicated with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>. With all PIs and NNRTI co-administration, monitor EKG (QTc) and serum levels: Target: 2 to 5 mcg/mL.</TD>
</TR>
<TR>
<TD valign="top"><B>Raltegravir</B></TD><TD valign="top">Interaction unlikely. </TD><TD valign="top">No data with LPV/r. <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (100 mg BID) did not affect RAL PK parameters. Consider usual dose with close monitoring of virologic efficacy. </TD>
</TR>
<TR>
<TD valign="top"><B>Ranitidine</B></TD><TD valign="top">No interaction</TD><TD valign="top">Use standard dose LPV/r tablet with ranitidine co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifabutin
          </B></TD><TD valign="top">Rifabutin AUC increased by 203%. LPV serum level increased 20% (NS).</TD><TD valign="top">Dose: LPV/r 3 caps bid +&nbsp;rifabutin 150 mg qod.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifapentine
          </B></TD><TD valign="top">LPV serum levels may be significantly decreased.</TD><TD valign="top">Avoid co-administration. Consider using rifabutin.</TD>
</TR>
<TR>
<TD valign="top"><B>Rosiglitazone</B></TD><TD valign="top">LPV AUC increased by 20% and Cmin increased by 21%. </TD><TD valign="top">Use standard dose. Limited sample size (NS) (n=4).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rosuvastatin
          </B></TD><TD valign="top">&nbsp;Rosuvastatin AUC and Cmax increased 2.1 to 4.7-fold, respectively. LPV and <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> PK parameters not significantly affected.</TD><TD valign="top">&nbsp;Use with close monitoring due to limited clinical data. Use low dose rosuvastatin and titrate slowly.</TD>
</TR>
<TR>
<TD valign="top"><B>Sildenafil</B></TD><TD valign="top">May increase sildenafil serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with close monitoring. Do not exceed 25 mg in 48-hrs.</TD>
</TR>
<TR>
<TD valign="top"><B>Simvastatin</B></TD><TD valign="top">May significantly increase simvastatin levels.</TD><TD valign="top">Contraindicated. Alternative HMG-CoA reductase inhibitor that may be used include pravastatin, cerivastatin, fluvastatin. Monitor for adverse effects due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Sirolimus</B></TD><TD valign="top">May significantly increase serum levels of sirolimus.</TD><TD valign="top">Applies to all PIs: Dose sirolimus based on serum levels. A significantly reduction of sirolimus dose with all PIs co-administration is highly likely.</TD>
</TR>
<TR>
<TD valign="top"><B>St. John's wort</B></TD><TD valign="top">May significantly decrease LPV serum levels.</TD><TD valign="top">Contraindicated. Studies only done with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> but St. John's wort likely to increase metabolism of other PIs and NNRTIs. Use an alternative (more effective) antidepressant.</TD>
</TR>
<TR>
<TD valign="top"><B>Tacrolimus</B></TD><TD valign="top">Tacrolimus increased 10-fold with co-administration. Several case reports of toxic serum levels of tacrolimus upon initiation of LPV/r.</TD><TD valign="top">Dose tacrolimus based on serum levels. A much lower dose (0.5-1 mg/week or 1/20-1/10 of standard dose) may be sufficient with LPV/r co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Tadalafil</B></TD><TD valign="top">May increase serum level of tadalafil.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Start with 5 mg. Do not exceed 10 mg in 72 hrs. Consider sildenafil due to more clinical data and shorter half-life allowing for easier titration.</TD>
</TR>
<TR>
<TD valign="top"><B>Tamoxifen</B></TD><TD valign="top">May increase serum level of tamoxifen.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of tamoxifen- induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Teniposide</B></TD><TD valign="top">May increase serum level of teniposide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of teniposide induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Terfenadine</B></TD><TD valign="top">May significantly increase terfenadine serum levels.</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>THC</B></TD><TD valign="top">Based on data with NFV and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> interactions are unlikely.</TD><TD valign="top">Applies to PIs and NNRTIs: Interactions are unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Trazadone</B></TD><TD valign="top">May increase serum levels of trazadone.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (SSRI:escitalopram, citalopram, sertraline, or fluoxetine).</TD>
</TR>
<TR>
<TD valign="top"><B>Trazodone </B></TD><TD valign="top">Trazodone AUC increased by 2.4 fold with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> co-administration. </TD><TD valign="top">Data limited to <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> co-administration. Use with caution. Nausea, dizziness, hypotension and syncope have been reported with co-administration. Consider decreasing trazodone dose by 50% with co-administration.<BR>
</TD>
</TR>
<TR>
<TD valign="top"><B>
            Triazolam
          </B></TD><TD valign="top">May significantly increase triazolam serum levels.</TD><TD valign="top">Contraindicated. Consider alternative benzodiazepines(temazepam, oxazepam, or lorazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Vardenafil</B></TD><TD valign="top">May significantly increase serum levels of vardenafil.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Do not exceed vardenafil 2.5 mg in 72 hrs (with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>) or 2.5 mg in 24 hrs (with other PIs and DLV). Consider sildenafil due to more clinical data and less pronounced interaction. Avoid co-administration with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>.</TD>
</TR>
<TR>
<TD valign="top"><B>Verapamil</B></TD><TD valign="top">May increase serum levels of verapamil.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and DLV have the potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Vinblastine</B></TD><TD valign="top">May increase serum levels of vinblastine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of vinblastine- induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Vincristine</B></TD><TD valign="top">May increase serum levels of vincristine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of vincristine- induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Vitamin C </B></TD><TD valign="top">Data limited to interaction study with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> and vitamin C (1 g/d): <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC decreased by 14% and Cmin by 32%. <BR>
</TD><TD valign="top">Clinical significance unknown. Other PI and NNRTI serum levels may be affected when co-administered with similar dose of vitamin C. </TD>
</TR>
<TR>
<TD valign="top"><B>&nbsp;Voriconazole&nbsp;</B></TD><TD valign="top">May significantly decrease voriconazole AUC. Voriconazole may increase LPV. </TD><TD valign="top">Significant interaction with <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> and <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (400mg bid); contraindicated. Voriconazole AUC decreased 39% with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg/d co-administration; avoid co-administration with boosted PI. Consider another antifungal for aspergillosis (i.e ambisome or caspofungin) or use with TDM. Voriconazole dose may need to be increased. </TD>
</TR>
<TR>
<TD valign="top"><B>Warfarin </B></TD><TD valign="top">A case report of increased warfarin requirement after <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> initiation. <BR>
</TD><TD valign="top">Other PIs and NNRTIs may also affect warfarin requirements. Monitor INR closely with co-administration. </TD>
</TR>
</TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>Major resistance mutations have not been identified.</li>
<li>Resistance develop from multiple PI mutations. </li>
<li>Primary PI mutations (32I, L33F, 82A/F/T/S, 84V/A/C, 90M, 46I/L) and secondary PI mutations (10, 20, 24, 47, 53, 54, 71, 73): &gt;4 mutations: decrease potency of LPV/r. </li>
<li>I50V: selected by APV; reduces susceptibility to LPV. </li>
<li>63P: reduced susceptibility to LPV when combined with other PI mutations. </li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10FF8"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>Inhibition of HIV protease, which results in nonfunctional, immature and non-infectious virions.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                Tabs: food increases bioavailability by 27%. Caps and oral solution:increased in bioavailability by 48% and 80%, respectively, when administered with moderate fat meal (23-25% of calories from fat).</li>
<li>Metabolism and Excretion: 
                Primarily biliary excretion with less than 3% excreted unchanged in the urine.</li>
<li>Protein Binding: 
                98-99%.</li>
<li>Cmax, Cmin, and AUC: 
                LPV/r 400 mg bid at steady-state: Mean Cmax = 9.8 (+/- 3.7) mcg/mL; Cmin = 7.1 (+/-2.9) mcg/mL; AUC 92.6 (+/- 36.7) mcg/mL hr</li>
<li>T1/2: 
                5-6 hrs</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>Use with caution in ESLD. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category C. No treatment-related malformation seen in animal studies. No embryonic and fetal development toxicities seen in rabbits. No human data available.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>No data. Breastfeeding in HIV-infected pts is not recommended in the U.S.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<ul>
<li>Pros: Long-term efficacy as initial therapy with potency retained at VL&gt;100,000; good pharmacokinetic profile that exceed IC50 by &gt;25-fold throughout dosing interval,&nbsp;enabling LPV/r to have activity against some PI resistant strains. Decreased pill burden with new tablet formulation. Better CD4 response compared to <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-containing regimen, and less resistance with failure.</li>
<li>Cons: GI intolerance,&nbsp;hyperlipidemia, and/or insulin resistance in some pts. More GI toxicity than with some other boosted PIs. Inferior to <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-containing regimen in PI-naive patients. DRV/r and TPV/r preferred for highly experienced pts, and DRV/r may have advantage even in LPV-susceptible, PI-experienced pts.</li>
</ul>
<a name="N11041"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>&nbsp;&nbsp;Johnson M, Grinsztejn B, Rodriguez C, et al.;
		&nbsp;96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.;        
		AIDS. 2006;20(5):711-8. ;
		2006; Vol. 
		20(5) ; pp. 
		711-8. ;
		<br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16514301&amp;dopt=abstract" target="_new">16514301 </a>
<br>
<b>Comments:</b>358 pts who have failed at least 2 HAART regimens containing at least 1 PI, NNRTI, or NRTI randomized to <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>&nbsp;300 + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>100 mg qd, <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> 400 mg/1200 mg qd, or LPV 400 mg/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>100 mg bid each combined with<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564"> TDF </A>+ 1 NRTI. Not all pts were heavily PI-experienced. At 48 wks, trend favoring LPV/r arm (46% vs 38% VL &lt;50, p=NS). However, at 96 wks, virologic suppression comparable between <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>/r and LPV/r treated patients. Mean reduction in VL -2.29 and -2.08 log&nbsp;in&nbsp;<A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>/r and LPV/r groups, respectively. Virologic response rates higher with &lt;4 PI mutations at baseline. In pts with 4 or more PI mutations, an undetectable viral load achieved in only 20% and 23% in <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>/r and LPV/r, respectively. Total cholesterol (+9%) and fasting TG (+30%) higher in LPV/r treated group. Grade 2-4 diarrhea less common in <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>/r pts (3%) vs. LPV/r (13%) pts.. &nbsp;Study limitations: unknown % of critical PI mutations,&nbsp;only 1/3&nbsp;on a PI-containing regimen at time of genotype analysis, post-hoc analysis of the truly PI-experienced underpowered to show differences between groups. <br>
<br>
</li>
<li>Riddler SA, Haubrich R, DiRienzo G, et al. ;
		A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. ;        
		Program and abstracts of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract THLB0204.;
		2006; Vol. 
		<br>
<b>Comments:</b>753 ARV-naive pts randomized to 3 regimens: LPV/r + NRTIs, <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> + NRTIs, and LPV/r + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>. At 96 wks, 89% of pts in&nbsp;<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> + 2&nbsp;NRTIs arm had VL &lt;50 vs. 77% in LPV/r + 2 NRTIs arm (p=0.003). LPV/r + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> arm had similar virologic efficacy compared to <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> + 2 NRTIs. No difference between 3 arms in time to first treatment-limiting toxicity. Despite superior virologic response in the <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>&nbsp;+&nbsp;2 NRTIs regimen, LPV/r containing regimen resulted in higher CD4 increase (241 vs. 285, p=0.01). In pts with virologic failure, development of resistance more common in&nbsp;<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> + 2 NRTIs arm than either LPV/r-containing arm. <br>
<br>
</li>
<li>Dragsted UB, Gerstoft J, Youle M, et al.;
		A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.;        
		Antivir Ther;
		2005; Vol. 
		10; pp. 
		735-43;
		<br>ISSN:
	        	1359-6535;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16218173&amp;dopt=abstract" target="_new">16218173</a>
<br>
<b>Comments:</b>This trial compared LPV/r (400/100 mg bid) with SQV/e (1000+ 100 mg bid) + at least 2 NRTI/NNRTIs in 324 pts. Population was heterogenous (33% naive and 32% who had virologic failure of at least 1 PI). At 48 wks, treatment failure occurred in 29/163 (18%) and 53/161 (33%) of patients in the LPV/r and SQV/r arms, respectively (ITT, p=0.002, log rank test). Risk of discontinuation also higher in <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> arm (30% vs 14%, p=0.0001). No overall difference in risk of grade 3 and 4 ADRs in the 2 arms. <br>
<br>
</li>
<li>Cohen C, Nieto-Cisneros L, Zala C, et al.;
		Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.;        
		Curr Med Res Opin;
		2005; Vol. 
		21; pp. 
		1683-92;
		<br>ISSN:
	        	0300-7995;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16238909&amp;dopt=abstract" target="_new">16238909</a>
<br>
<b>Comments:</b>Phase III trial comparing <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> (400 mg qd) with LPV/r (400/100 mg bid), in combination with 2 NRTIs, in 300 experienced pts with virologic failure following single PI-based regimen. At 48 wks, LPV/r resulted in significantly greater reduction in VL than unboosted <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> (-2.02 vs -1.59 log, p &lt; 0.001). Unboosted <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> is inferior to LPV/r for salvage. <br>
<br>
</li>
<li>&nbsp;DeJesus E, LaMarca A, Sension M, Beltran C, Yeni P;
		&nbsp;The Context Study: Efficacy and Safety of GW433908/RTV in PI-experienced Subjects with Virological Failure (24 Week Results). ;        
		<A class="headLines" target="_new" href="http://www.retroconference.org/2003/cd/Abstract/178.htm">10th CROI, Boston, Massachusetts. February 10-14, 2003; Abstract 178</A>.i;
		2003; Vol. 
		<br>
<b>Comments:</b>Open label, randomized study of 315 pts who had experienced virologic failure to 1 or 2 prior PI-containing regimens. Med. CD4 263 and VL 4.14 log. Time-average change in VL from baseline at 48-wks: -1.53 log for bid FPV/r and -1.76 log for LPV/r, a difference of 0.244 (97.5% CI -0.017, 0.561). VL &lt;50 through wk 48 in 37%, 46%, and 50% on qd FPV/r, bid FPV/r, and LPV/r, respectively. QD-FPV/r performed poorly and should not be used in PI-experienced pts. Trend favoring LPV/r, although the time-average change in VL from baseline not statistically different from bid FPV/r. In PI-experienced pts, <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> 700 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg bid was not "non-inferior" to LPV/r as defined by the time-average decline in VL from baseline. Study underpowered for secondary endpoint of VL &lt;50 at 48 wks.<br>
<br>
</li>
<li>Bongiovanni M, Bini T, Adorni F, et al.;
		Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.;        
		Antivir Ther;
		2003; Vol. 
		8; pp. 
		209-14;
		<br>ISSN:
	        	1359-6535;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=12924537&amp;dopt=abstract" target="_new">12924537</a>
<br>
<b>Comments:</b>Independent predictive factors related to virologic success with LPV/r regimens are VL and number of mutations at baseline; each additional log of VL reduced probability of virological success by 34.0% and each extra mutation by 14.5%. <br>
<br>
</li>
<li>Walmsley S, Bernstein B, King M, et al.;
		Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.;        
		N Engl J Med;
		2002; Vol. 
		346; pp. 
		2039-46;
		<br>ISSN:
	        	1533-4406;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=12087139&amp;dopt=abstract" target="_new">12087139 </a>
<br>
<b>Comments:</b>Prospective, double-blind trial involving 653 naive pts randomized to LPV/r + d4T + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> or <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> + d4T + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>. Pts were well matched at baseline with med. CD4 count of 232 and VL 5.01-4.98 log10 c /ml. At wk 48, more pts treated with LPV/r than <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> had HIV RNA &lt;400 (75% vs. 63%, p &lt;0.001) and &lt;50 (67% vs. 52%, p &lt;0.001).Discontinuation rate due to ADR was 3.4 % among pts receiving LPV/r and 3.7% among pts receiving NFV. In pts with virologic failure, genotypic resistance was observed in 25 of 76 NFV-treated patients (33 percent) and none of 37 patients treated with lopinavir-<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A> (P&lt;0.001). <br>
<br>
</li>
</ol>
<a name="REFERENCED WITHIN THIS GUIDE"></a>
<h2 class="grayLineHeaderBar">REFERENCED WITHIN THIS GUIDE</h2>
<ul>
<li>
<A class="headLines" target="_new" href="atazanavire910.html?contentInstanceId=9998&amp;siteId=429188">Atazanavir</A>
</li>
<li>
<A class="headLines" target="_new" href="efavirenze910.html?contentInstanceId=9998&amp;siteId=429188">Efavirenz</A>
</li>
<li>
<A class="headLines" target="_new" href="fosamprenavire910.html?contentInstanceId=9998&amp;siteId=429188">Fosamprenavir</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/initial_regimen_for_arv_therapy6eb2.html?contentInstanceId=432947&amp;siteId=429188">Initial Regimen for ARV Therapy</A>
</li>
<li>
<A class="headLines" target="_new" href="lamivudine6eb2.html?contentInstanceId=432947&amp;siteId=429188">Lamivudine</A>
</li>
<li>
<A class="headLines" target="_new" href="nelfinavir6eb2.html?contentInstanceId=432947&amp;siteId=429188">Nelfinavir</A>
</li>
<li>
<A class="headLines" target="_new" href="nevirapinee910.html?contentInstanceId=9998&amp;siteId=429188">Nevirapine</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/nutrition_care_and_support6eb2.html?contentInstanceId=432947&amp;siteId=429188">Nutrition Care and Support</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/post-exposure_prophylaxis6eb2.html?contentInstanceId=432947&amp;siteId=429188">Post-exposure prophylaxis</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/pregnancy_and_perinatal_transmission__zambia_specific_6eb2.html?contentInstanceId=432947&amp;siteId=429188">Pregnancy and perinatal transmission (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="../antimicrobial_agents/proguanil6eb2.html?contentInstanceId=432947&amp;siteId=429188">Proguanil</A>
</li>
<li>
<A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin6eb2.html?contentInstanceId=432947&amp;siteId=429188">Rifampicin</A>
</li>
<li>
<A class="headLines" target="_new" href="saquinavir6eb2.html?contentInstanceId=432947&amp;siteId=429188">Saquinavir</A>
</li>
<li>
<A class="headLines" target="_new" href="tenofovir6eb2.html?contentInstanceId=432947&amp;siteId=429188">Tenofovir</A>
</li>
<li>
<A class="headLines" target="_new" href="zidovudine6eb2.html?contentInstanceId=432947&amp;siteId=429188">Zidovudine</A>
</li>
<li>
<A class="headLines" target="_new" href="../antimicrobial_agents/artemether_lumefantrine6eb2.html?contentInstanceId=432947&amp;siteId=429188">artemether/lumefantrine</A>
</li>
</ul>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_lopinavir_ritonavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:43 GMT -->
</html>
